/WST
West Pharmaceutical Services, Inc.
WST • NYSEWST • NYSE • Healthcare
$235.55-1.62%-3.87
$235.55-1.62%(-3.87)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
73Low Risk
Momentum
32Negative
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
35.9%▲1.2pp
Revenue after COGS
Operating
20.1%▼0.5pp
After operating expenses
Net
16.1%▼1.0pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
40.3
Price vs earnings
EV/EBITDA
27.0
Enterprise value
FCF Yield
2.4%
Cash generation
Earnings Yield
2.5%
Inverse of P/E
Capital Efficiency
14
GoAI Quality ScoreFair
ROEReturn on Equity
15.5%Strong
ROAReturn on Assets
11.6%Strong
ROICReturn on Invested Capital
13.6%Strong
Financial Health
Current RatioHealthy
3.02
Short-term solvency (>1.5)
Net Debt / EBITDANet Cash
-0.52x
Debt repayment capacity (<3x)
Income QualityStrong
1.53
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B |
| Gross Profit | $1.10B | $1.00B | $1.13B | $1.14B | $1.17B |
| Gross Margin | 35.9% | 34.6% | 38.4% | 39.5% | 41.5% |
| Operating Income | $617.40M | $594.60M | $710.90M | $763.50M | $758.70M |
| Net Income | $493.70M | $492.70M | $593.40M | $585.90M | $661.80M |
| Net Margin | 16.1% | 17.0% | 20.1% | 20.3% | 23.4% |
| EPS | $6.83 | $6.75 | $7.99 | $7.88 | $8.90 |
Average Price Target
$303.33▲ 28.8% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for West Pharmaceutical Services, Inc., the average price target is $303.33, with a high forecast of $340.00 and a low forecast of $265.00. The average price target represents a 28.8% increase from the current price of $235.55.
Highest
$340.00
Average
$303.33
Lowest
$265.00
Rating Distribution
Strong Buy
0
0%
Buy
10
71%
Hold
3
21%
Sell
1
7%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Barclays● Maintain
Equal Weight
2026-02-13Evercore ISI Group● Maintain
Outperform
2026-02-03Barclays● Maintain
Equal Weight
2025-10-27UBS● Maintain
Buy
2025-10-24Keybanc● Maintain
Overweight
2025-10-24Evercore ISI Group● Maintain
Outperform
2025-10-23Barclays● Maintain
Equal Weight
2025-10-02UBS● Maintain
Buy
2025-07-25Evercore ISI Group● Maintain
Outperform
2025-07-25Barclays● Maintain
Equal Weight
2025-07-25Earnings History & Surprises
BEAT RATE
89%
Last 18 quarters
AVG SURPRISE
+12.3%
EPS vs Estimate
BEATS / MISSES
16/2
Last 18 quarters
LATEST EPS
$2.04
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+11.5%
$2.04 vs $1.83
Q4 '25
+16.7%
$1.96 vs $1.68
Q3 '25
+21.9%
$1.84 vs $1.51
Q2 '25
+18.9%
$1.45 vs $1.22
Q1 '25
+6.4%
$1.82 vs $1.71
Q4 '24
+23.3%
$1.85 vs $1.50
Q3 '24
-12.6%
$1.52 vs $1.74
Q2 '24
+23.8%
$1.56 vs $1.26
Q1 '24
+2.8%
$1.83 vs $1.78
Q4 '23
+16.1%
$2.16 vs $1.86
Q3 '23
+9.3%
$2.11 vs $1.93
Q2 '23
+18.6%
$1.98 vs $1.67
No investor questions available.
Latest News
No news available